Industry's colonization of psychiatry: Ethical and practical implications of financial conflicts of interest in the DSM-5

Feminism and Psychology

Volumn 23, Issue 1, 2013, Pages 93-106

  Cosgrove, Lisa ^a,b   Wheeler, Emily E ^b  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

diagnosis; ethics; financial conflicts of interest

Indexed keywords

EID: 84873663920     PISSN: 09593535     EISSN: 14617161     Source Type: Journal    
DOI: 10.1177/0959353512467972     Document Type: Review

References (66)

1. Ads for SSRI Antidepressants Are Misleading, Researchers Say [Press release]. (7 November 2005). Available at: http://www.eurekalert.org/pub_releases/2005-11/plos-afs103105.php.
2. Alcoff L.The politics of postmodern feminism, revisited.Cultural Critique. 1997;36:5-27.
3. Ali ABias in Psychiatric Diagnosis. Caplan PJCosgrove L, ed. New York, NY: Jason Aronson; 2004:71-75.
4. Diagnostic and Statistical Manual of Mental Disorders. 1980) Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Alexandria, VA: Author.Alexandria, VA: Author; 1980:.
5. Andreasen NC.DSM and the death of phenomenology in America: An example of unintended consequences.Schizophrenia Bulletin. 2007;33 (1): 108-112.
6. Angell M (2011) The illusion of psychiatry. The New York Review of Books. Available at: http://www.nybooks.com/articles/.
7. Barad KMeeting the Universe Halfway: Quantum Physics and the Entanglement of Matter and Meaning. Durham, NC: Duke University; 2007:.
8. Becker AEBias in Psychiatric Diagnosis. Caplan PJCosgrove L, ed. Lanham, MD: Jason Aronson; 2004:207-212.
9. Bernstein RJBeyond Objectivism and Relativism: Science, Hermeneutics, and Praxis. Philadelphia, PA: University of Pennsylvania Press; 1983:.
10. Bohr NThe Philosophical Writings of Niels Bohr, Vol I: Atomic Theory and the Description of Nature. Woodbridge, CT: Oxbow Press; 1963:.
11. Bohr NThe Philosophical Writings of Niels Bohr, Vol IV: Causality and Complementarity. Woodbridge, CT: Oxbow Press; 1998:.
12. Brandeis L.What publicity can do.Harper's Weekly. 1913;58 (2972): 10-13.
13. Cain DM,Lowenstein G,Moore DA.The dirt on coming clean: Perverse effects of disclosing conflicts of interest.Journal of Legal Studies. 2005;31 (1): 1-25.
14. Callaghan GM,Chacon C,Coles C, et al.An empirical evaluation of the diagnostic criteria for premenstrual dysphoric disorder: Problems with sex specificity and validity.Women & Therapy. 2009;32 (1): 1-21.
15. Caplan PJThey Say You're Crazy: How the World's Most Powerful Psychiatrists Decide Who's Normal. Reading, MA: Addison-Wesley; 1995:.
16. Caplan PJ.The debate about PMDD and Sarafem.Women & Therapy. 2004;27 (3-4): 55-67.
17. Caplan PJ,McCurdy-Myers J,Gans M.Should 'premenstrual syndrome' be called a psychiatric abnormality?.Feminism & Psychology. 1992;2 (1): 27-44.
18. Chesler PWomen and Madness. 1972) Women and Madness, 1st ed. Garden City, NY: Doubleday.Garden City, NY: Doubleday; 1972:.
19. Chrisler JC,Caplan PJ.The strange case of Dr. Jekyll and Ms. Hyde: How PMS became a cultural phenomenon and a psychiatric disorder.Annual Review of Sex Research. 2002;13:274-306.
20. Cosgrove L,Bursztajn HJ,Krimsky S, et al.Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines.Psychotherapy and Psychosomatics. 2009;78 (4): 228-232.
21. Cosgrove L,Caplan PJBias in Psychiatric Diagnosis. Caplan PJCosgrove L, ed. Lanham, MD: Jason Aronson; 2004:221-230.
22. Cosgrove L,Krimsky S.A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: A pernicious problem persists.PLoS Medicine. 2012;9 (3): e1001190-e1001190.
23. Cosgrove L,Krimsky S,Vijayaraghavan M, et al.Financial ties between DSM-IV panel members and the pharmaceutical industry.Psychotherapy and Psychosomatics. 2006;75 (3): 154-160.
24. Cosgrove L,Riddle BBias in Psychiatric Diagnosis. Caplan PJCosgrove L, ed. Lanham, MD: Jason Aronson; 2004:127-140.
25. Di Giulio GG,Reissing ED.Premenstrual dysphoric disorder: Prevalence, diagnostic considerations, and controversies.Journal of Psychosomatic Obstetrics & Gynecology. 2006;27 (4): 201-210.
26. Fee DPathology and the Postmodern: Mental Illness as Discourse and Experience. London: Sage; 2000:.
27. Foucault MMichel Foucault: Beyond Structuralism and Hermeneutics. 1983) On the genealogy of ethics: An overview of work in progress. In: DreyfusHLRabinowP (eds) Michel Foucault: Beyond Structuralism and Hermeneutics, 2nd ed. Chicago: The University of Chicago Press, pp. 231-232.Dreyfus HLRabinow P, ed. Chicago: The University of Chicago Press; 1983:231-232.
28. Frances A (2010) It's not too late to save 'normal.' LA Times. Available at: http://articles.latimes.com/.
29. Gallant SJ,Popiel DA,Hoffman DM, et al.Using daily ratings to confirm premenstrual syndrome/late luteal phase dysphoric disorder. Part II: What makes a "real" difference?.Psychosomatic Medicine. 1992;54:167-181.
30. Green S.Ethics and the pharmaceutical industry.Australasian Psychiatry. 2008;16 (3): 158-165.
31. Greene JAPrescribing by Numbers: Drugs and the Definition of Disease. Baltimore, MD: Johns Hopkins University; 2007:.
32. Halbreich H,Borenstein J,Pearlstein T, et al.The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).Psychoneuroendocrinology. 2003;28:1-23.
33. Hare-Mustin RT,Marecek JSeldom Seen, Rarely Heard: Women's Place in Psychology. Bohan JS, ed. Boulder, CO: Westview; 1992:227-249.
34. Hare-Mustin RT,Marecek JCritical Psychology: An Introduction. Fox DPrilleltensky I, ed. Thousand Oaks, CA: Sage; 1997:104-120.
35. Kaplan M.A woman's view of DSM-III.American Psychologist. 1983;38 (7): 786-792.
36. Kirk SA,Kutchins HThe Selling of DSM: The Rhetoric of Science in Psychiatry. Hawthorne, NY: Aldine de Gruyter; 1992:.
37. Krimsky SScience in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research?. Lanham, MD: Rowman and Littlfield; 2003a:.
38. Krimsky S.Small gifts, conflicts of interest, and the zero-tolerance threshold in medicine.The American Journal of Bioethics. 2003b;3 (3): 50-52.
39. Jasanoff SDesigns on Nature: Science and Democracy in Europe and the United States. Princeton, NJ: Princeton University; 2005:.
40. Lakoff APharmaceutical Reason: Knowledge and Value in Global Psychiatry. Cambridge, UK: Cambridge University; 2005:.
41. Lessig L (2009) Institutional Corruption [Video File]. Available at: http://link.brightcove.com/services/player/bcpid59085832001?bclid=58806604001&bctid=59505322001.
42. Lexchin J,O'Donovan O.Prohibiting or 'managing' conflict of interest?: A review of policies and procedures in Three European Drug Regulation Agencies.Social Science & Medicine. 2010;70 (5): 643-647.
43. Licurse A,Barber E,Joffe S, et al.The impact of disclosing financial ties in research and clinical care: A systematic review.Archives of Internal Medicine. 2010;170 (8): 675-682.
44. Marecek J.Disappearances, silences, and anxious rhetoric: Gender in abnormal psychology textbooks.Journal of Theoretical and Philosophical Psychology. 1993;13 (2): 114-123.
45. Matheson A.Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry.BioSocieties. 2008;3:355-382.
46. Moynihan R.Merging of marketing and medical science.BMJ: British Medical Journal. 2010;341:698-670.
47. Moynihan R,Heath I,Henry D.Selling sickness: The pharmaceutical industry and disease mongering.BMJ: British Medical Journal. 2002;324:886-890.
48. Murdoch DNiels Bohr's Philosophy of Physics. New York: Cambridge University Press; 1987:.
49. Parker IP,Georgaca E,Harper D, et alDeconstructing Psychopathology. London: Sage; 1995:.
50. Pilecki BC,Clegg JW,McKay DD.The influence of corporate and political interests on models of illness in the evolution of the DSM.European Psychiatry. 2011;26 (3): 194-200.
51. Does conflict of interest disclosure worsen bias?.PLoS Med. 2012;9 (4): e1001210-e1001210.
52. Potts A,Grace V,Gavey N, et al.Viagra stories': Challenging 'erectile dysfunction.Social Sciences & Medicine. 2004;59 (3): 489-499.
53. Prilleltensky I.Psychology and the status quo.American Psychologist. 1989;44:795-802.
54. Prilleltensky I.Values, assumptions, and practices: Assessing the moral implications of psychological discourse and action.American Psychologist. 1997;52 (5): 517-535.
55. Prilleltensky I,Nelson GBDoing Psychology Critically: Making a Difference in Diverse Settings. New York: Palgrave Macmillan; 2002:.
56. Quanstrum KH,Hayward RA.Lessons from the mammography wars.The New England Journal of Medicine. 2010;363 (11): 1076-1079.
57. Relman AS,Angell M.America's other drug problem: How the drug industry distorts medicine and politics.The New Republic. 2002;227 (25): 27-41.
58. Ronson J (2011) Bipolar kids: Victims of the 'madness industry'? New Scientist 2815: 44-47. Available at: http://www.newscientist.com.
59. Sismondo S.How pharmaceutical industry funding affects trial outcomes: Causal structures and responses.Social Science & Medicine. 2008;66 (9): 1909-1914.
60. Stoppard JM.Sexism and the DSM-III-R.Canadian Psychology. 1991;32 (2): 148-150.
61. Tiefer LA New View of Women's Sexual Problems. Kaschak ETiefer L, ed. New York: Haworth Press; 2001:63-98.
62. Ussher JMWomen's Madness: Misogyny or Mental Illness?. Amherst, MA: University of Massachusetts Press; 1991:.
63. Ussher JM.The role of premenstrual dysphoric disorder in the subjectification of women.Journal of Medical Humanities. 2003;24 (1-2): 131-146.
64. Ussher JM,Hunter M,Browne SJCulture in Psychology. Squire C, ed. New York, NY: Routledge; 2000:87-99.
65. Wilson M.DSM-III and the transformation of American psychiatry: A history.American Journal of Psychiatry. 1993;150:399-410.
66. Wittchen H.Women-specific mental disorders in DSM-5: Are we failing again?.Archives of Women's Mental Health. 2010;13 (1): 51-55.